Jeffrey A. Kline
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey A. Kline has a total of 502 co-authors. Here are the top co-authors by number of shared publications:
D. Mark Courtney
11 shared publications- Carlos Arturo Camargo
Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, United States
9 shared publications - Michael Alexander Puskarich
Department of Emergency Medicine, University of Minnesota, Minneapolis, MN 55364, USA
9 shared publications Christopher Kabrhel
8 shared publications- Lauren K. Stewart
Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
8 shared publications Alan E. Jones
Department of Emergency Medicine, University of Mississippi, Jackson (A.E.J.).
6 shared publications
Latest Publications
- 26 October 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (20) , 2791-2793
Improving the Conversation Around Mechanical Thrombectomy for Acute Pulmonary Embolism
- 26 October 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (20) , 2791-2793
Improving the Conversation Around Mechanical Thrombectomy for Acute Pulmonary Embolism
- Open Access
- 13 June 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (4)
Designing a web-based factorial survey experiment on diagnostic evaluation of cardiovascular symptoms in emergency care
- 13 June 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (4)
Open AccessDesigning a web-based factorial survey experiment on diagnostic evaluation of cardiovascular symptoms in emergency care
- Open Access
- 19 April 2026
- Published by Elsevier in SSRN Electronic Journal
Laboratory Virus Test Positivity Is not Associated with Increased Venous Thromboembolism Risk among Patients Presenting with Acute Respiratory Illnesses to U.S. Emergency Departments
Background: A major concern in emergency departments is whether the risk of developing venous thromboembolism (VTE) is increased among acute respiratory illness (ARI) patients with positive virus tests.Methods: This serial cross-sectional study uses data collected prospectively by the U.S. CDC-sponsored Respiratory Virus Laboratory Emergency Department Network Surveillance (RESP-LENS) program from August 2021 to September 2024. Standardized protocols were used to rigorously collect clinical information from consecutive patients of all ages who presented to 91 hospitals with an acute respiratory illness (ARI). Case definition of ARI was from predefined set of international classification of disease (ICD) codes. Hazard ratios with 95% confidence intervals were estimated using time-varying Cox proportional hazards models with robust standard errors.Findings: A total of 1,106,634 unique patients presented had 1,391,306 encounters during the study period and 66% of encounters included laboratory virus testing. Excluding untested patient encounters, 18% of tested patient encounters were positive for SARS CoV-2, 3% for RSV, 7% for influenza and 2% for multiple viruses. There were 16,123 individual patients who received a VTE ICD-10 code within 30 days, resulting in a study period prevalence rate of 1∙46% (95%CI 1∙43%-1∙48%).Compared to patients with negative test results, virus test positivity was not significantly associated with VTE among discharged ED patients, inpatients or the subset transferred to the ICU, adjusting for patient demographics (age, race, sex), smoking status and clinical comorbidities (prior VTE, pulmonary disorders, cardiometabolic disorders, cancer, HIV/AIDS, and organ transplant).Similarly adjusted models showed that VTE was significantly associated with increased adjusted hazard of in- hospital mortality among ED patients and inpatients, but not among the subset transferred to the ICU (HR[95%CI]: 7 [3∙7-13], 1∙6 [1∙3-2], 1.1 [0∙7-1∙9], respectively. Virus test positivity did not modify the observed associations between VTE and in-hospital mortality in each of the three denominator groups (interaction p- value > 0∙25).Interpretation: In the U.S. from August 2021 to September 2024, laboratory confirmed virus infection was not associated with increased risk of short-term VTE diagnosis or death among patients seeking emergency care
- 19 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLaboratory Virus Test Positivity Is not Associated with Increased Venous Thromboembolism Risk among Patients Presenting with Acute Respiratory Illnesses to U.S. Emergency Departments
Background: A major concern in emergency departments is whether the risk of developing venous thromboembolism (VTE) is increased among acute respiratory illness (ARI) patients with positive virus tests.Methods: This serial cross-sectional study uses data collected prospectively by the U.S. CDC-sponsored Respiratory Virus Laboratory Emergency Department Network Surveillance (RESP-LENS) program from August 2021 to September 2024. Standardized protocols were used to rigorously collect clinical information from consecutive patients of all ages who presented to 91 hospitals with an acute respiratory illness (ARI). Case definition of ARI was from predefined set of international classification of disease (ICD) codes. Hazard ratios with 95% confidence intervals were estimated using time-varying Cox proportional hazards models with robust standard errors.Findings: A total of 1,106,634 unique patients presented had 1,391,306 encounters during the study period and 66% of encounters included laboratory virus testing. Excluding untested patient encounters, 18% of tested patient encounters were positive for SARS CoV-2, 3% for RSV, 7% for influenza and 2% for multiple viruses. There were 16,123 individual patients who received a VTE ICD-10 code within 30 days, resulting in a study period prevalence rate of 1∙46% (95%CI 1∙43%-1∙48%).Compared to patients with negative test results, virus test positivity was not significantly associated with VTE among discharged ED patients, inpatients or the subset transferred to the ICU, adjusting for patient demographics (age, race, sex), smoking status and clinical comorbidities (prior VTE, pulmonary disorders, cardiometabolic disorders, cancer, HIV/AIDS, and organ transplant).Similarly adjusted models showed that VTE was significantly associated with increased adjusted hazard of in- hospital mortality among ED patients and inpatients, but not among the subset transferred to the ICU (HR[95%CI]: 7 [3∙7-13], 1∙6 [1∙3-2], 1.1 [0∙7-1∙9], respectively. Virus test positivity did not modify the observed associations between VTE and in-hospital mortality in each of the three denominator groups (interaction p- value > 0∙25).Interpretation: In the U.S. from August 2021 to September 2024, laboratory confirmed virus infection was not associated with increased risk of short-term VTE diagnosis or death among patients seeking emergency care
- Open Access
Impact of Venous CONgestion on Organ Function and Outcomes in Sepsis (ICON-Sepsis): a prospective observational cohort study protocol
Introduction Sepsis is a common condition with significant morbidity, mortality and annual costs of care in the billions of dollars. Despite innumerable studies on the causes of, and therapies for, sepsis, the mortality rate has not changed substantially in the last 20 years. Treatments remain generic, with current guidelines recommending the same approach for all patients, regardless of the litany of differences that exist at baseline. Moreover, the blanket administration of 30 cc/kg of intravenous fluid (IVF) to all patients is recognised as being directly harmful to some. Patient-level heterogeneity in prior sepsis trials is recognised as a substantial contributor to all these problems, yet no prior investigation has attempted to identify volume-informed septic phenotypes, a necessary first step towards precision care. Methods and analysis Predicated on prior studies demonstrating detectability of organ-level congestion, we hypothesise that central venous hypertension (1) is deleterious to the function of the lungs, liver, kidneys and vascular endothelium; (2) is worsened by cardiac dysfunction and IVF administration; and (3) contributes to adverse organ-specific and overall outcomes. Beginning in the emergency department, cardiac function will be assessed with echocardiography while congestion in the lungs and kidneys will be assessed using previously validated sonographic markers of congestion. Biomarkers for each organ will be collected concurrently, thereby increasing the fidelity of our phenotypic profiles by pairing indicators of macroscopic and microscopic stress and dysfunction. Data will also be collected at 24 hours and 7 days (or discharge, whichever comes first) after presentation. Classical and machine learning approaches will be used to analyse our large data stream and develop a rule-based system to identify distinct subpopulations of patients with sepsis who have greater risk/likelihood of both organ-specific and overall adverse outcomes. Ethics and dissemination This project has been approved by the Wayne State University Institutional Review Board, with patient enrolment beginning in April 2024. Findings will be reported and disseminated via conference presentations and open-access publications.
Open AccessImpact of Venous CONgestion on Organ Function and Outcomes in Sepsis (ICON-Sepsis): a prospective observational cohort study protocol
Introduction Sepsis is a common condition with significant morbidity, mortality and annual costs of care in the billions of dollars. Despite innumerable studies on the causes of, and therapies for, sepsis, the mortality rate has not changed substantially in the last 20 years. Treatments remain generic, with current guidelines recommending the same approach for all patients, regardless of the litany of differences that exist at baseline. Moreover, the blanket administration of 30 cc/kg of intravenous fluid (IVF) to all patients is recognised as being directly harmful to some. Patient-level heterogeneity in prior sepsis trials is recognised as a substantial contributor to all these problems, yet no prior investigation has attempted to identify volume-informed septic phenotypes, a necessary first step towards precision care. Methods and analysis Predicated on prior studies demonstrating detectability of organ-level congestion, we hypothesise that central venous hypertension (1) is deleterious to the function of the lungs, liver, kidneys and vascular endothelium; (2) is worsened by cardiac dysfunction and IVF administration; and (3) contributes to adverse organ-specific and overall outcomes. Beginning in the emergency department, cardiac function will be assessed with echocardiography while congestion in the lungs and kidneys will be assessed using previously validated sonographic markers of congestion. Biomarkers for each organ will be collected concurrently, thereby increasing the fidelity of our phenotypic profiles by pairing indicators of macroscopic and microscopic stress and dysfunction. Data will also be collected at 24 hours and 7 days (or discharge, whichever comes first) after presentation. Classical and machine learning approaches will be used to analyse our large data stream and develop a rule-based system to identify distinct subpopulations of patients with sepsis who have greater risk/likelihood of both organ-specific and overall adverse outcomes. Ethics and dissemination This project has been approved by the Wayne State University Institutional Review Board, with patient enrolment beginning in April 2024. Findings will be reported and disseminated via conference presentations and open-access publications.
- Open Access
- 23 May 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4) , 102900
Diagnostic accuracy of the international classification of disease “I26” code to detect acute pulmonary embolism in a surveillance network
- 23 May 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4) , 102900
Open AccessDiagnostic accuracy of the international classification of disease “I26” code to detect acute pulmonary embolism in a surveillance network
- Open Access
- 3 March 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (3) , e250636
Therapy Dogs for Anxiety in Children in the Emergency Department
Importance: Prior evidence suggests that the use of therapy dogs in emergency care reduces anxiety in adults, but no trial has tested the use of therapy dogs in emergency care of children.Objective: To examine whether adjunctive use of therapy dogs in standard child-life therapy reduces child-reported and parent-reported child anxiety in a pediatric emergency department (ED).Design, Setting, and Participants: This randomized clinical trial was conducted from February 1, 2023, to June 30, 2024, at an academic pediatric ED. Children (aged 5-17 years) with suspected moderate to high anxiety were included.Intervention: All participants received standard child-life therapy, and the intervention group was randomly assigned to have exposure to a therapy dog and handler for approximately 10 minutes.Main Outcomes and Measures: Anxiety was measured using the 0- to 10-point FACES scale (with 0 indicating no anxiety and 10 indicating very severe anxiety) and salivary cortisol concentrations. Measurements were obtained at baseline (T0), 45 minutes (T1), and 120 minutes (T2) for both child and parents.Results: A total of 80 patients (mean [SD] age, 10.9 [3.8] years; 45 [56%] female) were enrolled (40 in the control group and 40 in the intervention group). At T0, the mean (SD) FACES scores were 5.4 (2.8) for child report and 6.4 (2.4) for parent report; the means were not different between groups. From T0 to T1, child-reported anxiety changed by a mean (SD) of −1.5 (3.4) points in the control group vs −2.7 (2.5) points in the intervention group (P = .02, Mann-Whitney U test); similarly, mean (SD) parent-estimated child anxiety changed by −1.8 (2.7) points in the control group vs −3.2 (2.3) points in the intervention group (P = .008). A total of 9 children (23%) in the control group had a greater than 2.5-point decrease in FACES score vs 18 (46%) in intervention group (P = .04, Fisher test). At T2, mean (SD) child-reported FACES scores decreased to 3.6 (3.4) points in the control group and 3.0 (2.7) points in the intervention group (P = .70). A total of 14 control participants (35%) received ketamine, midazolam, lorazepam, or droperidol vs 7 (18%) in the intervention group (P = .08, Fisher test). Child and parent salivary cortisol decreased from T0 to T1 in both groups but was not different between groups. Parental salivary cortisol was significantly consistently higher than their children’s salivary cortisol (P < .001, unpaired t test, for comparisons of child vs parent at T0 and T1 in both groups).Conclusions and Relevance: This study of adjunctive use of therapy dogs in standard child-life therapy found a modest but significantly greater reduction in both child-reported and parental-reported child anxiety in the pediatric ED for the intervention vs control group. These findings support the use of therapy dogs to help reduce pain and anxiety without the use of chemical or physical constraint.Trial Registration: ClinicalTrials.gov Identifier: NCT03784573
- 3 March 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (3) , e250636
Open AccessTherapy Dogs for Anxiety in Children in the Emergency Department
Importance: Prior evidence suggests that the use of therapy dogs in emergency care reduces anxiety in adults, but no trial has tested the use of therapy dogs in emergency care of children.Objective: To examine whether adjunctive use of therapy dogs in standard child-life therapy reduces child-reported and parent-reported child anxiety in a pediatric emergency department (ED).Design, Setting, and Participants: This randomized clinical trial was conducted from February 1, 2023, to June 30, 2024, at an academic pediatric ED. Children (aged 5-17 years) with suspected moderate to high anxiety were included.Intervention: All participants received standard child-life therapy, and the intervention group was randomly assigned to have exposure to a therapy dog and handler for approximately 10 minutes.Main Outcomes and Measures: Anxiety was measured using the 0- to 10-point FACES scale (with 0 indicating no anxiety and 10 indicating very severe anxiety) and salivary cortisol concentrations. Measurements were obtained at baseline (T0), 45 minutes (T1), and 120 minutes (T2) for both child and parents.Results: A total of 80 patients (mean [SD] age, 10.9 [3.8] years; 45 [56%] female) were enrolled (40 in the control group and 40 in the intervention group). At T0, the mean (SD) FACES scores were 5.4 (2.8) for child report and 6.4 (2.4) for parent report; the means were not different between groups. From T0 to T1, child-reported anxiety changed by a mean (SD) of −1.5 (3.4) points in the control group vs −2.7 (2.5) points in the intervention group (P = .02, Mann-Whitney U test); similarly, mean (SD) parent-estimated child anxiety changed by −1.8 (2.7) points in the control group vs −3.2 (2.3) points in the intervention group (P = .008). A total of 9 children (23%) in the control group had a greater than 2.5-point decrease in FACES score vs 18 (46%) in intervention group (P = .04, Fisher test). At T2, mean (SD) child-reported FACES scores decreased to 3.6 (3.4) points in the control group and 3.0 (2.7) points in the intervention group (P = .70). A total of 14 control participants (35%) received ketamine, midazolam, lorazepam, or droperidol vs 7 (18%) in the intervention group (P = .08, Fisher test). Child and parent salivary cortisol decreased from T0 to T1 in both groups but was not different between groups. Parental salivary cortisol was significantly consistently higher than their children’s salivary cortisol (P < .001, unpaired t test, for comparisons of child vs parent at T0 and T1 in both groups).Conclusions and Relevance: This study of adjunctive use of therapy dogs in standard child-life therapy found a modest but significantly greater reduction in both child-reported and parental-reported child anxiety in the pediatric ED for the intervention vs control group. These findings support the use of therapy dogs to help reduce pain and anxiety without the use of chemical or physical constraint.Trial Registration: ClinicalTrials.gov Identifier: NCT03784573
- 4 February 2025
- Published by Wiley in Academic Emergency Medicine
- Vol. 32 (3) , 198-199
Introduction to the AEM special issue on the science of errors in emergency care, 2025
- 4 February 2025
- Published by Wiley in Academic Emergency Medicine
- Vol. 32 (3) , 198-199
Introduction to the AEM special issue on the science of errors in emergency care, 2025
- Open Access
- 15 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf004
Laboratory Confirmation of Respiratory Syncytial Virus Infection Is Not Associated With an Increased Risk of Death in Adults With Acute Respiratory Illness
Background: Limited data have described the testing patterns and outcomes of adults (≥18 years) with acute respiratory illness (ARI) in the emergency department setting. Methods: This prospective cohort study includes patients with ARI from a program sponsored by the Centers for Disease Control and Prevention entitled Respiratory Virus Laboratory Emergency Department Network Surveillance (RESP-LENS) from August 2021 until March 2024 (91 hospitals). Patients with ARIs were identified weekly by electronic surveillance for 1 or more of 130 ICD-10 codes that defined ARI. Patients were followed for 30 days for the primary outcomes of hospitalization and mortality. Testing for RSV with nasopharyngeal swabbing followed by reverse transcription polymerase chain reaction was done as part of usual care. Risk of 30-day mortality and RSV positivity was tested in a generalized estimating equation. Results: From 1 210 394 patients with ARI, 345 185 (28.5%) adults underwent RSV testing, which was positive in 2.4%. In adults who were RSV+, the overall mortality rate was 1.9% as compared with 2.9% in adults who were RSV−. Mortality with RSV+ status increased with age ≥65 years to 3.8% (95% CI, 3.1%–4.5%). However, in the generalized estimating equation, RSV+ status was not associated with a higher rate of hospitalization (adjusted odds, 0.79; 95% CI, .75–.84) or 30-day mortality (odds, 0.62; 95% CI, .53–.74) relative to those who were RSV–. Age ≥65 years, incremental worsening of vital signs, male sex, and heart failure were independently associated with death. Conclusions: Among adults with ARI presenting to an emergency department who were tested for RSV as part of their usual care, laboratory-confirmed RSV positivity was not associated with increased risk, including hospitalization, intensive care unit requirement, or death.
- 15 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf004
Open AccessLaboratory Confirmation of Respiratory Syncytial Virus Infection Is Not Associated With an Increased Risk of Death in Adults With Acute Respiratory Illness
Background: Limited data have described the testing patterns and outcomes of adults (≥18 years) with acute respiratory illness (ARI) in the emergency department setting. Methods: This prospective cohort study includes patients with ARI from a program sponsored by the Centers for Disease Control and Prevention entitled Respiratory Virus Laboratory Emergency Department Network Surveillance (RESP-LENS) from August 2021 until March 2024 (91 hospitals). Patients with ARIs were identified weekly by electronic surveillance for 1 or more of 130 ICD-10 codes that defined ARI. Patients were followed for 30 days for the primary outcomes of hospitalization and mortality. Testing for RSV with nasopharyngeal swabbing followed by reverse transcription polymerase chain reaction was done as part of usual care. Risk of 30-day mortality and RSV positivity was tested in a generalized estimating equation. Results: From 1 210 394 patients with ARI, 345 185 (28.5%) adults underwent RSV testing, which was positive in 2.4%. In adults who were RSV+, the overall mortality rate was 1.9% as compared with 2.9% in adults who were RSV−. Mortality with RSV+ status increased with age ≥65 years to 3.8% (95% CI, 3.1%–4.5%). However, in the generalized estimating equation, RSV+ status was not associated with a higher rate of hospitalization (adjusted odds, 0.79; 95% CI, .75–.84) or 30-day mortality (odds, 0.62; 95% CI, .53–.74) relative to those who were RSV–. Age ≥65 years, incremental worsening of vital signs, male sex, and heart failure were independently associated with death. Conclusions: Among adults with ARI presenting to an emergency department who were tested for RSV as part of their usual care, laboratory-confirmed RSV positivity was not associated with increased risk, including hospitalization, intensive care unit requirement, or death.